Ranibizumab (Lucentis) has become the first drug treatment to be approved in Australia for the treatment of proliferative diabetic retinopathy (PDR). The Therapeutic Goods Administration (TGA) has approved ranibizumab for the treatment of adults with the eyesight-threatening condition, which is currently treated with panretinal laser photocoagulation (PRP) therapy. The anti-vascular endothelial growth factor (anti-VEGF) antibody ...
TGA approves ranibizumab for proliferative diabetic retinopathy
By Michael Woodhead
15 Sep 2020